Table 1.
Summary of immunotherapy studies for uveal melanoma (UM).
| Study | Study Design | Number of Patients | Elevated LDH at Baseline | Therapy | Best Response | Overall Response Rate (CR + PR) | Median Duration of Response (mo) |
Disease-Control Rate (CR + PR + SD) | Durable Disease-Control Rate (CR + PR + SD ≥ 6 mo) | Median PFS/DFS (mo) |
AEs Grade ≥3 % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| [24] | case series, stage-IV UM |
14 | 21% | dendritic-cell vaccination | SD | 0% | n.a. | 71% | 21% | n.a. | 0 |
| [26] | adjuvant, open-label, phase-II study, UM | 23 | n.a. | adjuvant dendritic-cell vaccination | n.a. | n.a. | n.a. | n.a. | n.a. | 34.5 | 0 |
| [30] | multicentre, phase-II, stage-IV UM |
53 | 38% | ipi 3 mg/kg Q3W | SD | 0% | n.a. | 47% | 21% | 2.8 | 36%, one death |
| [31] | retrospective, multicentre, stage-IV UM |
pembro: 54 | 57% | pembro 2 mg/kg Q3W | PR | 4.7% | n.a. | 22.7% | n.a. | 3.1 | 7% |
| nivo: 32 | 53% | nivo 3 mg/kg Q2W | PR | 4.7% | n.a. | 18.7% | n.a. | 2.8 | 13%, one death | ||
| ipi + PD-1 ab: 15 total: 86 |
47% | ipi 3 mg/kg + nivo 1 mg/kg Q3W, followed by nivo 3 mg/kg Q2W ipi 1 mg/kg + pembro 2 mg/kg Q3W, followed by pembro 2 mg/kg Q3W ipi 1 mg/kg + nivo 3 mg/kg Q3W, followed by nivo 3 mg/kg Q2W |
PR | 16.7% | n.a. | 33.4% | n.a. | 2.8 | 13% | ||
| [32] | retrospective, multicenter, stage-IV UM |
pembro: 38 nivo: 16 atezo: 2 total: 56 |
71% | pembro 2 mg/kg Q3W 10 mg/kg Q2W 10 mg/kg Q3W Unknown Q3W nivo 1 mg/kg Q2W 2 mg/kg Q2W 3 mg/kg Q2W 10 mg/kg Q2W atezo 10 mg/kg Q2W 15 mg/kg Q2W |
PR | 3.6% | n.a. | 12.5% | 8.9% | 2.6 | 13% |
| Case series HD, 2019 (unpublished) |
retrospective, monocentre, stage-IV UM |
pembro: 12 nivo: 1 ipi + nivo: 7 total: 20 |
55% | pembro 2 mg/kg Q3W nivo 3 mg/kg Q2W ipi 3 mg/kg + nivo 1 mg/kg Q3W, followed by nivo 3 mg/kg Q2W |
PR | 11.8% | 2.85 | 29.4% | 5.9% | 2.75 | 30% |
| [33] | prospective, phase-II, multicentre, open-label, single-arm, stage-IV UM |
50 | 32% | ipi 3 mg/kg + nivo 1 mg/kg Q3W, followed by nivo 3 mg/kg Q2W | PR | 12% | n.a. | 64% | n.a. | 3.3 | 54%, one death |
| [46,47] | phase-I study, prospective, stage-IV UM |
19 | 73% | tebentafusp (IMCgp100) | PR | 11% | 7.1 | 71% | 41% | 5.6 | 79% |
| [52] | interim analysis of a monocentre, two-stage, single-arm, phase-II study, stage-IV UM |
21 | 52% | adoptive T-cell therapy | CR | 35% | 4+ | 43% | 10% | n.a. | 100%, one death |
LDH, lactate dehydrogenase; UM, uveal melanoma; pembro, pembrolizumab; nivo, nivolumab; ipi, ipilimumab; atezo, atezolizumab; PD-1 ab, PD-1 antibody; CR, complete response; PR, partial response; SD, stable disease; HD, National Center for Tumor Diseases, University Hospital Heidelberg; n.a., not assessed; Q2W, every two weeks; Q3W, every three weeks; PFS, progression-free survival; DFS, median disease-free survival; mo, months; AEs, adverse events; death, treatment-related death.